Browse the evidence

In overweight or obese adults with type 2 diabetes, patterns of weight regain or weight cycling following intentional weight loss do not significantly increase the risk of incident fractures or significantly reduce bone mineral density compared to sustained weight loss/maintenance.

If you have type 2 diabetes and are overweight, you do not need to fear that regaining some weight after a successful loss will increase your risk of breaking a bone. Studies show that the fracture risk for people who regain or cycle weight is similar to those who maintain their weight loss. Focus on maintaining overall health rather than stressing over minor weight fluctuations.

Pioglitazone, a thiazolidinedione, significantly reduces the risk of developing type 2 diabetes in patients with impaired glucose tolerance and stabilizes beta-cell function, with a favorable cardiovascular safety profile compared to rosiglitazone.

Pioglitazone is a powerful drug that can prevent diabetes and protect pancreatic beta-cells in people with prediabetes. It is more effective than metformin in some studies but can cause weight gain and fluid retention. It is generally reserved for cases where other treatments fail or are not suitable, due to its side effect profile.

Skeletal muscle UCP3 mRNA expression is primarily determined by the percentage of type I muscle fibers, showing a strong positive correlation (r=0.842), whereas resting energy expenditure and maximum oxygen consumption are not related to UCP3 levels.

Your muscle fiber type (specifically the proportion of slow-twitch Type I fibers) is a stronger predictor of your muscle's UCP3 gene expression than your current weight, age, or even your resting metabolic rate. While you cannot directly 'choose' your fiber type, endurance training can influence fiber characteristics. Focus on building slow-twitch dominant muscles through steady-state aerobic activity, as this is naturally associated with higher UCP3 mRNA levels, which may support fatty acid metabolism and oxidative stress defense.

Skeletal muscle UCP3 mRNA levels are positively correlated with plasma leptin and insulin concentrations, but this relationship is gender-dependent, remaining significant for insulin only in females.

In healthy women, higher insulin levels are associated with higher UCP3 gene expression in muscles, whereas this link is not observed in men. This suggests that hormonal regulation of metabolic genes is sex-specific. For women, managing insulin sensitivity through diet and exercise may indirectly support muscle metabolic health via UCP3 pathways, whereas for men, other factors like fiber type may be more dominant.

Skeletal muscle UCP3 mRNA levels decrease with age in healthy adults, inversely correlating with age (r = -0.411), independent of changes in resting energy expenditure.

As you age, your muscle's UCP3 gene expression tends to decline, even if your resting metabolic rate doesn't change proportionally. This decline might be linked to how your body handles oxidative stress rather than just energy burning. Maintaining muscle mass and oxidative capacity through regular exercise may help mitigate this age-related decline in UCP3 expression.

Exogenous testosterone administration (200 mg/week) does not alter whole-body energy expenditure, substrate oxidation, or skeletal muscle metabolic gene expression during a severe energy deficit in healthy men.

If you are a healthy man in a calorie deficit and exercising heavily, taking testosterone will not change how your body burns fat or carbs compared to not taking it. It helps preserve muscle mass, but it does not boost your metabolism or fat loss. Focus on your exercise volume and calorie intake for metabolic adaptations.

Achieving recommended target values for glycated hemoglobin (HbA1c <7%), systolic blood pressure (<140 mmHg), and LDL-cholesterol (<100 mg/dl) in patients with type 2 diabetes is not associated with reduced all-cause mortality.

For patients with Type 2 Diabetes, strictly hitting the standard numerical targets for blood sugar, blood pressure, and cholesterol may not lower your risk of death as much as previously thought. While these targets are still used for other health reasons, do not assume that achieving them guarantees longevity. Focus on overall health stability and discuss individualized goals with your doctor, as aggressive treatment might not yield the expected mortality benefit.

In individuals with type 2 diabetes who carry the haptoglobin (Hp) 2-2 phenotype, maintaining an HbA1c level below 6.5% does NOT significantly reduce the risk of coronary artery disease compared to levels of 7.0-7.9%.

If you have type 2 diabetes and have the haptoglobin 2-2 genetic variant, aiming for an HbA1c below 6.5% may not provide additional protection against heart disease compared to levels of 7.0-7.9%. This suggests that overly aggressive glycemic control might not be necessary or beneficial for cardiovascular health in this specific group.

Current precision nutrition products and nutrigenomics concepts promoted on social media frequently contain misleading or untrue information, particularly regarding the readiness of personalized diets and the ability of specific foods to alter DNA.

Be skeptical of social media posts claiming that specific diets or supplements can change your DNA or that personalized nutrition products are ready for general use. The scientific consensus is that these technologies are not yet ready for broad application, and many products contain misleading or untrue information. Focus on evidence-based dietary patterns rather than unproven genetic tailoring products.

In Type 2 Diabetes, Myocardial Infarction, Hypertension, and Sleep Apnea, elevated C-reactive protein (CRP) is primarily driven by adiposity rather than independent inflammatory pathology, as the association attenuates or reverses upon adjustment for BMI.

If you have high blood pressure, diabetes, or a history of heart issues, your high CRP (inflammation) is likely caused by your weight, not a separate inflammatory disease. Focus on weight loss through diet and lifestyle changes rather than seeking anti-inflammatory medications, as reducing adiposity directly reduces the inflammation.

In Chronic Kidney Disease, Heart Failure, Liver Disease, Psoriasis, Rheumatoid Arthritis, and COPD, elevated CRP is NOT explained by adiposity alone, indicating independent inflammatory pathology driven by end-organ damage or tissue-specific inflammation.

If you have CKD, Heart Failure, Liver Disease, Psoriasis, RA, or COPD, your high CRP is likely due to the disease process itself, not just your weight. While weight management is still beneficial, you likely need specific treatments targeting the organ damage or autoimmune response, as weight loss alone may not resolve the inflammation.

Switching from Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in women with HIV results in significant weight loss, indicating TDF has weight-suppressive effects.

If you are a woman with HIV and are gaining weight on a TAF-based regimen, ask your doctor about switching to TDF. Studies show this switch can lead to significant weight loss (approx. 1.6 kg) in women, likely because TDF suppresses weight gain compared to TAF.

Intensive lifestyle interventions (diet and exercise) aiming for weight loss and increased physical activity do not significantly reduce cardiovascular morbidity or mortality in patients with type 2 diabetes compared to standard care, despite improving surrogate markers.

While diet and exercise are crucial for feeling better and managing blood sugar, do not rely on them alone to prevent heart attacks or death in type 2 diabetes. You likely need medication to manage blood pressure and lipids alongside lifestyle changes to protect your heart.

In individuals with ideal cardiovascular health (high CVHS), elevated BMI (≥35.0 kg/m²) does not significantly increase the risk of incident atherosclerotic cardiovascular disease (ASCVD) compared to normal BMI, whereas low cardiovascular health strongly predicts ASCVD regardless of BMI.

If you have ideal cardiovascular health (normal blood pressure, lipids, glucose, no smoking, active, healthy diet, good sleep), your risk of heart disease is low even if your BMI is high (≥35). Focus on maintaining these healthy habits rather than trying to lose weight. If your cardiovascular health score is low, your risk is high regardless of your BMI, so prioritize improving lifestyle and metabolic markers.

Adults not recommended for weight loss treatment by obesity guidelines have significantly lower cardiovascular disease risk than those recommended for treatment, regardless of whether the 1998 or 2013 guidelines are used.

Being classified as 'needing weight loss' by current medical guidelines is associated with a higher risk of heart disease compared to being classified as 'not needing weight loss.' This does not mean weight loss is harmful, but it highlights that the guidelines are designed to flag high-risk patients, not necessarily those who will see the greatest cardiovascular benefit from losing weight.

The 2013 obesity guidelines perform similarly to the 1998 guidelines in discriminating CVD risk, with no significant improvement in identifying those who benefit from weight loss.

Switching from the 1998 to the 2013 obesity guidelines does not significantly improve the ability to predict who will have cardiovascular disease. The newer guidelines identify a slightly different group of people as needing treatment, but the overall risk prediction is similar.

High intake of food rich in saturated fat is not independently associated with subclinical atherosclerosis (measured by carotid intima-media thickness) or its progression in high-risk European adults after adjusting for lifestyle and demographic confounders.

For individuals at high risk of cardiovascular disease, simply reducing saturated fat intake may not be sufficient to reduce subclinical atherosclerosis markers like carotid intima-media thickness. Focus on overall lifestyle factors, including physical activity, smoking cessation, and managing other risk factors, as the isolated effect of saturated fat on this specific measure was not significant in this high-risk population.

Classifying individuals by a 'leptin phenotype' (relatively high or low leptin for a given body fat percentage) does not predict differential energy expenditure, metabolic adaptation, or susceptibility to weight change in response to caloric restriction or overfeeding.

Do not rely on fasting leptin levels to predict your weight loss success or failure. Whether your leptin is 'high' or 'low' for your body fat percentage does not appear to change how your body responds to dieting or overeating in terms of energy expenditure or weight change. Focus on sustainable caloric deficits and activity rather than hormonal profiling for prediction.

Markov models are the dominant methodological framework for economic evaluations of obesity interventions, with 85% of reviewed studies utilizing state-transition models.

When evaluating the long-term cost-effectiveness of obesity treatments, decision-makers should expect and look for Markov modeling. This is the standard approach for comparing interventions like bariatric surgery, pharmacotherapy, and lifestyle changes over a patient's lifetime.

Current Markov models for obesity interventions exhibit significant methodological heterogeneity, particularly in how they model the progression of obesity and its impact on costs and utilities.

When comparing economic evaluations of obesity treatments, be aware that different studies use different structures (direct BMI-to-cost vs. BMI-to-complications). This makes direct comparison difficult. Look for studies that use standardized validation and include a broad spectrum of complications.

Diabetes mellitus (DM) and cardiovascular disease (CVD) are the most frequently modeled obesity-related complications in Markov models, with DM appearing in 15/15 models focusing on complications and CVD in 14/15.

If you are looking at an economic evaluation of an obesity treatment, expect it to focus heavily on preventing diabetes and cardiovascular events. These are the main drivers of long-term cost savings and quality-of-life improvements in these models.

Validation practices in Markov models for obesity interventions are inconsistently reported, with only 43% of models reporting validation, limiting the reliability and comparability of these evaluations.

Be cautious when using economic evaluations of obesity treatments that do not report validation. Only 43% of the models reviewed reported validation, which limits their reliability. Look for studies that use standardized validation guidelines like ISPOR.

Bariatric surgery is not a guaranteed cure for type 2 diabetes, with significant rates of non-remission (20-40%) and recurrence (up to 50% at 10 years) occurring even after successful weight loss.

Do not assume bariatric surgery is a permanent cure for diabetes. Even with successful weight loss, a significant portion of patients experience diabetes recurrence or require continued medication. Post-surgical care must include ongoing glycemic monitoring and likely continued pharmacotherapy to manage residual metabolic issues.

Self-reported weight and height data significantly overestimates obesity prevalence compared to professional anthropometric measurements, rendering self-perception an inadequate tool for population-level nutritional classification.

Do not rely on your own memory of your weight and height for health decisions. Self-reports are statistically unreliable for detecting obesity. If you are concerned about your nutritional status, get measured by a professional using calibrated scales and stadiometers, as self-reporting tends to overestimate obesity prevalence by missing the true extent of the issue.